💎 #ESMO25 Presidential Session w/ @JeanneTie #ColorectalCancer – Phase III DYNAMIC-III: ctDNA-guided de-escalation after surgery in stage III colon cancer In ctDNA⁻ patients: ☄️ 3-year RFS 85.3% vs 88.1% (standard) 🎯 Oxaliplatin exposure reduced 88.6% ➜ 34.8% 💥 Fewer

DYNAMIC III deescalation study presented #esmo2025 did not meet prespecified endpoint, although missed it narrowly. Chemotherapy continues to be SOC for stage III colon cancer patients. #clinicaltrials Congratulations to Dr.Tie for her inspirational work in this field.

Honoured to present OCELOT data today @IASLC #WCLC2025 #LCSM on behalf of my Canadian coauthors.

Learning about the gut microbiome at #WCLC2024 with @ArielleElkrief

Great work Dr. Verma and the whole POWER team on this work. HER2 is not just for breast and stomach cancer, and the results are not binary +'ve(3+/2+ with ISH+) versus -'ve anymore. https://t.co/CgXcOPkJdY

Strong work by Drs. Saurav Verma and Mark Vincent, honoured to have been included. An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy https://t.co/G20BkrDe7q #mdpicancers via @Cancers_MDPI

Fellow Lung Cancer Researchers, if you are interested in publishing a review, editorial or original research on combination therapies in lung cancer in the official journal of @CAMO_ACOM Please reach out!

I had the privilege of collaborating with a group of Canadian experts, myself included, on a self-learning video platform. Our focus revolved around the management of oncology patients, and I encourage you to explore the video library available :

Sharing our review discussing efficacy, safety and future with ADCs in NSCLC - ‘Targeting’ Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer—An Updated Review https://t.co/WJCtLCT7QQ #mdpicurroncol via @CurrentOncology @JackRaph @DrDanBreadner

#boat2023 @OncEd is a great way to get the updates from ASCO AM across disease sites. And thrilled to be presenting updates along with Dr. Stephen Welch to represent LRCP @LHSCCanada A must attend for all medical oncologists, even if they were in Chicago

(1/3) Going to ASCO this week? Join us for Dr. Quincy Chu's oral presentation highlighting the phase 3 results of the IND.227 trial in mesothelioma: Time: Jun/3/2023, 3:00 PM-6:00 PM CDT Hall B1 https://t.co/HnpVyxeoaW @INDProgramCCTG @CDNCancerTrials #mesothelioma

Excited to see Dr Quincy Chu presenting IND227 at ASCO. @CDNCancerTrials @INDProgramCCTG

Congratulations to members @DrDanBreadner, Dr. Scott Ernst, Dr. Maria MacDonald, and Dr. Mark Vincent of @SchulichMedDent and @LHSCCanada for their recent MORF Grant funding. #ResearchMatters

Dr. Breadner explains why pancreatic cancer is still one of the more challenging cancers to diagnose and treat, and the importance of the work being done by researchers at The Baker Centre for Pancreatic Cancer.  Learn more: https://t.co/zpZy5VlO8y

Huge disappointment: @NovartisCanada & pan-Canadian pharmaceutical alliance (pCPA) failed to negotiate a dabrafenib/tremetinib price in BRAF+ lung ca. https://t.co/nRircqeBCX Bewildering as an agreement exists in melanoma. Lung ca pts being stigmatized - again? @LungCancer_Can

Excited to be presenting in the "Practical Discussions on Tumour Agnostic Implementation into Clinical Care in Ontario: Challenges and Opportunities" discussion on October 13, 2022 at 6:00PM EST! Click below to register: https://t.co/wBBmFjBS89

Bewildering decision from @CADTH_ACMTS to reject Tepotinib, an effective drug in the rare lung ca subtype MetEx14 mutation. https://t.co/TdtoGjfcdX. It’s approved by @US_FDA @EMA_News @NICEComms, also in QC by @INESSS_Qc, but the rest of Canada misses out! Really?@LungCancer_Can